IV Cocaine Abuse: A Laboratory Model - 3

This study has been completed.

First Received on September 20, 1999. Last Updated on June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Columbia University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000214

Purpose

The purpose of this study is to evaluate the effects of buprenorpine on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving in non-opiate dependent cocaine users.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Buprenorphine	Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	IV Cocaine Abuse: A Laboratory Model

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Direct cocaine effects (caridio, subjective)
Interaction of coc/bup on cardio measures
Ineraction of coc/bup on coc's subjective effects
Effects of buprenorphine on cocaine craving

Estimated Enrollment:	0
Study Start Date:	January 1992

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000214

Locations

United States, New York
Columbia University
New York, New York, United States, 10023

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Columbia University

Investigators

Principal Investigator:

Richard Foltin, Ph.D.

Columbia University

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000214 History of Changes
Other Study ID Numbers:	NIDA-06234-3, R01-06234-3
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotic Antagonists
Narcotics

ClinicalTrials.gov processed this record on February 12, 2012